To date, Qilu has launched 300+ products with 50+ products “First-to- launch” in China. The company has also fostered a robust pipeline including 200+ generic products, 30+ biosimilars and 80+ innovative products.
FINISHED DOSAGE FORMSLeading injectable and solid dose manufacturer with significant in-house development and manufacturing capabilities.Click to view +
ACTIVE PHARMACEUTICAL INGREDIENTSEquipped with large-scale manufacturing facilities for the production of chemically synthesized, lyophilized, sterile, crystallized and fermented APIs.Click to view +
Originated from QILU, Universal love to the WORLD
Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations. Qilu currently has 13 subsidiaries, 11 manufacturing sites and over 30000 employees worldwide, 70% of whom are with bachelor’s degree or above. It ranks No.8 in Chinese pharmaceutical industry by sales revenue in 2019. Dedicated to offering more affordable medicines to the world and improving people's well-being, Qilu has exported its products to over 80+ countries.
Qilu Pharmaceutical has always maintained an innovative development strategy guided by the market demand and is achieving its organic growth strategy utilizing a strong pool of 3000+ scientists spread across 5 R&D platforms based in the US (Seattle WA, Boston MA, San Francisco CA) and China (Shanghai, Jinan). To date, Qilu has launched 200+ products with 50+ products “First to launch” in China and 3 products “D181 launch” in US. The company has also a robust pipeline, including 200+ generic products, 30+ biosimilar products and 80+ innovative products.EXPLORE MORE >>
11 Domestic Manufacturing Sites
TOP 10 Chinese Pharma. & Industrial Enterprise
300+ Marketed Products
R & D
Clinical Value based & Patients- centered
The research team, comprised of over 3,000 members, fully utilizes the innovative drug R&D center technology with global independent intellectual property rights, targeting at the tumor and autoimmune diseases, the team has initiated over 60 new first-in-class drug projects. Qilu plans to market 10 to 12 innovative drugs in the next five years.